CohBar
在场
CohBar 是一家在股票代码 CWBR (US) 下上市的公司。
高管
查看带有其 7 名主要高管的组织结构图
CohBar 搜索最多的简介
- Joseph Sarret, Chief Executive Officer and Director
- David Greenwood, Chairman of The Board
- Albion Fitzgerald, Director
创建提醒
跟踪 CohBar 的高管变动
生物技术
CohBar 拥有 2,326 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- TRexBio 刚刚宣布为 84 筹款数百万美元。 (公布2024十一月14号).
- Trace Neuroscience 刚刚宣布为 101 筹款数百万美元。 (公布2024十一月14号).
- AvenCell Therapeutics 刚刚宣布为 112 筹款数百万美元。 (公布2024十一月11号).
生物技术 行业的其他推荐联系人
消息
CohBar 的最新新闻稿
- CohBar, Inc.: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (Form 8-K)
- CohBar Reports Second Quarter 2023 Financial Results
- Press Releases
- Morphogenesis, Inc. and CohBar, Inc. Announce Positive Results from Phase 1b Trial of IFx-Hu2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC)
- Morphogenesis, Inc. and CohBar, Inc. Announce Acceptance of Abstract for Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
- CohBar, Inc. and Morphogenesis, Inc. Enter into Definitive Merger Agreement to Advance an Innovative Late-stage Clinical Immuno-oncology Pipeline of Therapies to Overcome Resistance to Cancer Immunotherapy
- CohBar Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Progress
- CohBar to Announce 2022 Third Quarter Financial Results and Provide Business Update on November 8, 2022
- CohBar Announces Reverse Stock Split
- CohBar to Present at H.C. Wainwright 24th Annual Global Investment Conference
- View more press releases Close
通过电子邮件
